Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKB | Q96GD4 | 19/20 | 0.85 |
| ▸ | LCK | P06239 | 3/20 | 0.84 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.84 |
| ▸ | KDR | P35968 | 2/20 | 0.84 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.84 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.84 |
| ▸ | PTK6 | Q13882 | 1/20 | 0.84 |
| ▸ | FLT3 | P36888 | 1/20 | 0.69 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13155440 | 0.92 | AURKB (1.00) | AURKBLCKCHEK1KDRIRAK4 | |
| SCHEMBL12588161 | 0.91 | AURKB (1.00) | AURKBLCKCHEK1KDRIRAK4 | |
| SCHEMBL13155469 | 0.91 | AURKB (1.00) | AURKBLCKCHEK1KDRIRAK4 | |
| SCHEMBL13155442 | 0.91 | AURKB (1.00) | AURKBLCKCHEK1KDRIRAK4 | |
| SCHEMBL12588175 | 0.91 | AURKB (0.87) | AURKBLCKCHEK1KDRIRAK4 | |
| SCHEMBL13157606 | 0.88 | AURKB (0.85) | AURKBLCKCHEK1KDRIRAK4 | |
| SCHEMBL13155451 | 0.87 | AURKB (0.87) | AURKBLCKCHEK1KDRIRAK4 | |
| SCHEMBL13155444 | 0.87 | AURKB (0.84) | AURKBLCKCHEK1KDRIRAK4 | |
| SCHEMBL12588210 | 0.87 | AURKB (0.85) | AURKBLCKCHEK1KDRIRAK4 | |
| SCHEMBL12588156 | 0.87 | AURKB (0.86) | AURKBLCKCHEK1KDRIRAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008156614-A2 | IMIDAZOPYRAZINES AS PROTEIN KINASE INHIBITORS | SCHERING CORPORATION (US) | 2008-12-24 | — | — | WO | disclosed |